Skip to main content
For Healthcare Professionals

JARDIANCE®

Overview

Product overview

JARDIANCE® is indicated as a treatment to control blood glucose and to prevent CV death in adult patients with type 2 diabetes mellitus. JARDIANCE® is not recommended in patients with type 1 diabetes mellitus or to treat diabetic ketoacidosis. JARDIANCE® 10 mg is also indicated as a treatment of NYHA class II-IV heart failure with reduced left ventricular ejection fraction.1

Product key facts

product_key2

IndicationType 2 diabetes mellitus

  1. JARDIANCE® is indicated to improve glycemic control in adults with type 2 diabetes mellitus.1

  2. In adults with type 2 diabetes mellitus and established cardiovascular (CV) disease, JARDIANCE® can reduce the risk of CV death.1

Heart failure

  1. JARDIANCE® 10 mg is indicated in adult patients with heart failure (NYHA II-IV) and reduced left ventricular ejection fraction to reduce the risk of CV death or hospitalization for heart failure and slow the decline of estimated glomerular filtration rate (eGFR).1

product_key3

Active ingredients

Empagliflozin1

product_key4

Legal category

Prescription only medicine1

product_key6

Dosage form and drug content

Empagliflozin 10 mg film-coated tablets1

Empagliflozin 25 mg film-coated tablets1

product_Key7

Administration form

Oral administration1

product_key1

Pack sizes

One box contains 2-1000 tablets in ALU-PVC aluminum foil package.1

Taiwan NHIA reimbursement criteria2

JARDIANCE® is reimbursed under following conditions:

  • When JARDIANCE® is used in type 2 diabetes mellitus patients with inadequate glycemic control despite receiving treatment with maximum tolerated dose of metformin;
  • JARDIANCE® and dipeptidyl peptidase-4 (DPP-4) inhibitors should not be used concurrently with the fixed-dose combination containing both ingredients.
  • Do not exceed one tablet per day.

Footnotes:

  • CV, cardiovascular; DPP-4, dipeptidyl peptidase-4; NHIA, National Health Insurance Administration

References:

  1. JARDIANCE® approved package insert. Updated in October 2020 and approved in August 2021.

  2. Taiwan National Health Insurance Administration. Reimbursement criteria for hormones and drugs affecting hormonal mechanism. https://www.nhi.gov.tw/DL.aspx?sitessn=292&u=LzAwMS9VcGxvYWQvMjkyL3JlbGZpbGUvMC82MTMzL2NoYXA1XzExMDA2LnBkZg%3d%3d&n=Y2hhcDVfMTEwMDYucGRm&ico%20=.pdf  . Accessed 02 Aug 2021.

Related News

Reporting adverse events

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.